Biomarker qualification via public-private partnerships

S. L. Eck, S. M. Paul

Research output: Contribution to journalShort surveypeer-review

13 Scopus citations


Biomarkers linked to patient outcomes (safety and efficacy) have an increasingly important role in drug development. Consequently, validation and qualification of such biomarkers are essential, often requiring large data sets from well-controlled randomized clinical trials. In the December 2009 issue of Clinical Pharmacology Therapeutics, investigators utilizing data from four pharmaceutical companies and working under the auspices of the Biomarkers Consortium described the utility of adiponectin as an early predictor of glycemic control in diabetic patients taking peroxisome proliferator-activated receptor (PPAR) agonists. This work illustrates the advantages of large public-private partnerships for biomarker qualification.

Original languageEnglish
Pages (from-to)21-23
Number of pages3
JournalClinical pharmacology and therapeutics
Issue number1
StatePublished - Jan 2010


Dive into the research topics of 'Biomarker qualification via public-private partnerships'. Together they form a unique fingerprint.

Cite this